Skip to main content
TXG logo

10x Genomics, Inc. (TXG) Stock: Price, Forecast & Analyst Target

10x Genomics, Inc. (TXG) — MoonshotScore 38/100 (Weak band), calculated Nov 18, 2026. Price $57.07 (+1.37%), as of the Nov 18, 2026 trading session; market cap $7.51B. Expected results Feb 11, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 13.05× (cash as of Sep 30, 2026) · expected results Feb 11, 2027

$57.07 +$0.77 (+1.37%) Market Cap $7.51B

10x Genomics, Inc. · TXG · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: TXG sells instruments, experiment-specific consumables and software that let researchers examine biology at cell-resolved and spatial levels; it is a life-science tools supplier, not a drug developer. The case depends on whether Atera can revive spatial demand while recurring Chromium consumables sustain growth and the cost base moves toward durable profitability.

Price as of Nov 18, 2026

Key Statistics

38 of 100

MoonshotScore v2 · 10x Genomics (TXG)

Weak
Business Quality Solid (72)
Financial Safety Sound (77)
Valuation Rich (33)
Growth Durability Growing (67)
Momentum Surging (98)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.

Enterprise value relative to EBITDA is the main valuation drag relative to sector peers.

  • EPS beat 6 of the last 8 reports
  • Altman Z 17.41 · Piotroski F 5
  • ROE -8.2% · ROA -6.3% · current ratio 5.12 · earnings yield -0.9% · free-cash-flow yield 1.4%

Holding back: a rich price

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TXG (57 recorded, newest six shown)
RecordedScoreBand
39Weak
39Weak
39Weak
39Weak
38Weak
38Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$57.07
Change on the day+1.37%
52-week range$15.18–$102.81
Market capitalisation$7.51B—
Shares traded on the day2.10M
Beta (volatility vs the S&P 500)2.03

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $12, high $94, latest $57. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $94 $12 high $94 Feb 12, 2026 · Earnings results · reported above the recorded estimate · close $181May 7, 2026 · Earnings results · reported above the recorded estimate · close $222Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $523Nov 5, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $594Nov 5, 2026 · Earnings results · reported above the recorded estimate · close $595 Oct 17, 2025 Nov 18, 2026 · $57 $12Oct 17, 2025$14Oct 31, 2025$16Nov 14, 2025$19Nov 28, 2025$15Dec 12, 2025$16Dec 26, 2025$20Jan 9, 2026$22Jan 23, 2026$19Feb 6, 2026$19Feb 20, 2026$21Mar 6, 2026$18Mar 20, 2026$22Apr 2, 2026$26Apr 17, 2026$22May 1, 2026$21May 15, 2026$28May 29, 2026$29Jun 12, 2026$37Jun 26, 2026$43Jul 10, 2026$46Jul 24, 2026$52Aug 7, 2026$65Aug 21, 2026$63Sep 4, 2026$77Sep 18, 2026$94Oct 2, 2026$70Oct 16, 2026$70Oct 30, 2026$58Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • Additionally, as Atera instrument shipments ramp in the fourth quarter, we expect gross margins to step down sequentially.

    Adam Taich · Statement from

  • So like as we said, we expect to ship about 50 units by the end of this year.

    Serge Saxonov · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for 10x Genomics (TXG): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Moderate
Valuation Weak
Growth Durability Moderate
Momentum Strong

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is 10x Genomics (TXG), and what does it report?

Short answer · as of

Chromium and Chromium Connect prepare and analyze biological samples, while Visium maps gene activity within tissue.

Academic, government, biotechnology and biopharmaceutical laboratories buy the instruments and then use proprietary chips, slides and reagents as experiments run.

Reported revenue therefore measures much more than equipment placements. Consumables provide the dominant stream, with smaller contributions from instruments, services, licensing and royalties; experiment activity on the installed platforms matters more than instrument shipments alone.

2 · Latest results

What do the latest results show for 10x Genomics (TXG)?

Revenue was nearly flat sequentially in the latest period but remained below the comparable prior period. Gross profit improved from the immediately preceding period, yet higher selling and administrative expense accompanied a wider operating and net loss; operating cash flow stayed positive.

Recent reports have generally exceeded revenue expectations, but that has not restored consistent accounting profitability. Management attributes the expected near-term revenue step-down to the spatial platform transition and expects Atera shipments to become a more meaningful contributor later.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$150.67M Sep 30, 2026
Latest quarter · R&D
$52.93M Sep 30, 2026
Latest quarter · SG&A
$76.06M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$16.06M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$150.67M$52.93M$76.06M−$16.06M
Jun 30, 2026$151.04M$56.79M$78.66M−$19.55M
Mar 31, 2026$150.84M$56.85M$66.38M−$17.05M
Dec 31, 2025$166.03M$55.97M$76.62M−$19.54M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$150.67M Nov 5, 2026
Latest report · revenue estimate
$147.96M Nov 5, 2026
Latest report · revenue vs estimate
Above estimate Nov 5, 2026
Latest report · EPS vs estimate
Above estimate Nov 5, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 5, 2026$150.67M$147.96M−$0.1500−$0.2670
Aug 6, 2026$151.04M$146.67M−$0.1400−$0.2431
May 7, 2026$150.84M$146.41M−$0.1000−$0.2900
Feb 12, 2026$166.03M$159.65M−$0.1300−$0.1900
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$149M-$27M-$0.22 (diluted)
Q4 FY2025$166M-$16M-$0.13 (diluted)
Q1 FY2026$151M-$13M-$0.10 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for 10x Genomics (TXG)?

Short answer

Cash and short-term investments were $575.68M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $15.83M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Cash and short-term investments substantially exceed debt and total liabilities, and the cash balance has risen across the reported history. Operating cash flow has also remained positive through most recent periods while capital spending has been modest, giving the company room to fund product development without immediate balance-sheet pressure.

That liquidity does not resolve the earnings problem. Research, selling and administrative costs still exceed gross profit, trailing margins remain negative, and the valuation stands at a demanding multiple of sales; net cash represents only a modest portion of the equity value. A prolonged spatial transition or weaker experiment volumes would pressure the consumables stream that supplies most revenue.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$15.83M Sep 30, 2026
Previous quarter · operating cash flow
$16.97M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$15.83M−$970,000
Jun 30, 2026$16.97M−$1.59M
Mar 31, 2026$26.12M−$1.60M
Dec 31, 2025$40.78M−$1.78M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at 10x Genomics (TXG)?

Short answer · as of

The next earnings report is expected on Feb 11, 2027.

Atera shipment cadence is the most immediate operating marker. Management expects spatial transition effects to weigh on near-term revenue before shipments contribute more meaningfully later, so the useful test is whether that handoff appears in revenue without another deterioration in gross profit or operating loss.

Consumables should be watched alongside instruments because they reveal whether laboratories are actively running experiments rather than merely adopting hardware. Positive operating cash flow must also persist as consensus expectations pair revenue growth with continuing accounting losses.

What management is planning

Management's statements are quoted under Upcoming events

5 · Peer comparison

How does 10x Genomics compare with its peers?

Short answer

10x Genomics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

TXG belongs with life-science instrument and research-platform companies rather than therapeutic biotechnology developers. Its distinction is the combination of Chromium cell-resolved workflows, Visium spatial analysis, software and proprietary consumables, creating revenue from laboratory activity after hardware placement. The consumables-heavy mix makes research usage and platform transitions more consequential than a conventional equipment replacement cycle.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Globus Medical, Inc. (GMED) Same industry, near in market value$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.50 Nov 18, 2026$12.6B92 5-pillar Nov 18, 2026
LivaNova PLC (LIVN) Same industry, near in market value$94.54 Nov 18, 2026$5.21B88 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B85 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Named competitor$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$103.32 Nov 18, 2026$19.6B79 5-pillar Nov 18, 2026
Bio-Rad Laboratories, Inc. (BIO) Named competitor$370.17 Nov 18, 2026$9.95B77 5-pillar Nov 18, 2026
Integer Holdings Corporation (ITGR) Same industry, near in market value$126.97 Nov 18, 2026$4.32B68 5-pillar Nov 18, 2026
TransMedics Group, Inc. (TMDX) Same industry, near in market value$96.43 Nov 18, 2026$3.35B68 5-pillar Nov 18, 2026
Bruker Corporation (BRKR) Same industry, near in market value$63.26 Nov 18, 2026$9.66B59 5-pillar Nov 18, 2026
10x Genomics (TXG) — this page$57.07$7.51B38

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$61.00 – $110.00
Consensus target
$82.40
Median target
$75.00

Consensus record · Captured .

Measured against a quoted price of $57.07 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026

Transactions
44
Identified insiders
9
Purchases
0
Sales
36
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
503 Period end Sep 30, 2026
Previous quarter · holders
405 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Fmr LLC18,138,699
Price T Rowe Associates INC /Md/17,470,896
Blackrock, INC.11,574,445
Ark Investment Management LLC6,272,998
Vanguard Portfolio Management LLC5,914,697

Tracked investors

Which of the 16 named investors we follow held TXG in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20263.26%$566.83MTrimmed −37.3% shares
Viking GlobalAndreas HalvorsenQ3 20260.21%$67.51MNew position
Bridgewater AssociatesFounded by Ray DalioQ3 20260.05%$10.53MAdded +770.9% shares
Duquesne Family OfficeStanley DruckenmillerQ3 20260%$0Sold out (was $15.46M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about 10x Genomics (TXG)?

Read these with our analysis →

What Investors Ask About 10x Genomics (TXG) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How do Chromium instruments and consumables shape TXG revenue?

Chromium hardware establishes the workflow, while chips, slides and reagents are consumed as laboratories run experiments. Consumables dominate reported revenue, so usage of installed systems is the more persistent economic engine.

Why does the Visium transition to Atera matter for TXG?

Management expects the spatial transition to suppress near-term revenue before Atera shipments become a more meaningful contributor. The transition matters because delayed adoption can weaken instrument revenue and the later consumable demand attached to those platforms.

Why can Chromium and Visium sales coexist with accounting losses?

The platforms generate strong gross profit, but research and development plus selling and administrative expense still consume more than that profit. Operating cash flow can remain positive even while operating and net results are negative.

Who buys Chromium and Visium systems?

Academic, government, biotechnology and biopharmaceutical organizations use the systems for cell-resolved and spatial analysis of biological samples. Their purchases span instruments, consumables, services and software-supported workflows.

What is the TXG stock price today?

The last price recorded for 10x Genomics, Inc. (TXG), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TXG price target?

The analyst consensus price target for 10x Genomics, Inc. (TXG), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 79 figures on this page — 2 from SEC filings and earnings calls, 68 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • 1. What is 10x Genomics (TXG), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for 10x Genomics (TXG)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for 10x Genomics (TXG)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Cash against market value; Revenue by segment
  • 4. What should you watch next at 10x Genomics (TXG)?: Management outlook — dated call excerpts; Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Revenue by segment; Reported versus estimated, last 8 quarters
  • 5. How does 10x Genomics compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Trailing twelve-month ratio set
  • FAQ: How do Chromium instruments and consumables shape TXG revenue?: Business description; Revenue by segment
  • FAQ: Why does the Visium transition to Atera matter for TXG?: Management outlook — dated call excerpts; Revenue by segment; Next earnings report
  • FAQ: Why can Chromium and Visium sales coexist with accounting losses?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: Who buys Chromium and Visium systems?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold TXG

Funds in our ETF coverage that list TXG among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
ARK Innovation ETF (ARKK)3.43%